Wild-Type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients

Chinese Journal of Cancer Research

Volumn 23, Issue 4, 2011, Pages 271-275

  Gao, Jing ^a   Wang, Ting Ting ^a   Yu, Jing Wei ^a   Li, Yan Yan ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

BRAF; Cetuximab; Colorectal cancer; KRAS; Mutation

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHINESE; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE; ONCOGENE B RAF; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84863032616     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-011-0271-4     Document Type: Article

References (21)

1. Venook AP. Epidermal growth factor receptor targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103:2435-46. (Pubitemid 40800520)
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8. (Pubitemid 41079832)
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45. (Pubitemid 38944402)
4. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10. (Pubitemid 46211358)
5. Hebbar M, Wacrenier A, Desauw C, et al. Lack of useful- ness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17:855-7. (Pubitemid 44310182)
6. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327:298-303. (Pubitemid 17075080)
7. Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in human colon. J. Natl. Cancer Inst 1993; 85:200-4.
8. Lievre A, Bachet JB, Boige V, et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9. (Pubitemid 351171687)
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutation and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65.
10. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69:1851-7.
11. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:2622-9.
12. Li FH, Shen L, Li ZH, et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16:5881-8.
13. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931-7.
14. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101:715-21.
15. Di Nicolantonio FD, Martini M, Molinari F, et al. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. J Clin Oncol 2008; 26:5705-12.
16. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. J Clin Oncol 2009; 27:5924-30.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
18. Heinemann V, Stintzing S, Kirchner T, et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35:262-71.
19. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumori- genesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934. (Pubitemid 34976022)
20. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62:6451-5. (Pubitemid 35364105)
21. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003; 22:6455-7. (Pubitemid 37281692)